-
Site License
-
Site License
-
Enterprisewide
-
Enterprisewide
Emerging Medical Sensing Technologies
Frost & Sullivan, September 2008, Pages: 126
This research service provides an overview of the emerging sensing technologies in the field of healthcare.
This Frost & Sullivan research service titled Emerging Medical Sensing Technologies provides in-depth information about various commercial diagnostic products and biosensing techniques available in the market today and those on the verge of commercialization. It examines the scope of biosensors with respect to their applications across varied healthcare-related areas, including drug delivery, medical devices, and nanomedicine. It aims to increase the market and product awareness among not only key industry participants but also the medical community and the patients themselves. In this research, Frost & Sullivan's expert analysts thoroughly examine the following technologies: non-invasive sensors, invasive devices, nanotechnology-based sensors, diagnostic test kits, and medical devices for medical diagnostic applications.
Market Overview
Biosensors' Efficacy in the Healthcare Industry Drives Advances in Medical Sensing Technologies
The healthcare sector's need for simpler and easier alternative methods of diagnosis, coupled with patients' demand for user-friendly, cost-effective techniques, have given a major impetus to the development of medical sensing technologies such as biosensors. This efficient, compatible, and user-friendly technology, which can detect minute quantities of biochemical or chemical components in a biological medium, has found growing acceptance among a wide range of applications in the field of ailment detection as well as analytical diagnosis. Owing to the increasing impact of nanotechnology as well as microarray and microfluidic technologies, both the medical sensing industry as well as academia are working toward developing new biosensor platforms for pain-free, accurate, and selectively sensitive diagnostic biosensors. A greater number of collaborations between the industry and universities will go a long way in the creation of newer and better biosensors. "Researchers have now designed new-age biosensors that are non-biological elements capable of sensing biological parameters, which means that the sensing element in question works only in presence of the proposed biological element," say the analysts of this research. Such improvements in biosensing are timely, considering the spurt in diseases all over the world due to unhealthy lifestyles, inadequate physical activity, and unreasonable occupational demands.
Despite all these advances, biosensors are still challenged by the limited lifetimes of their biological components since all organic materials, mainly when removed from their natural surroundings, deteriorate with time. "Generally, it has been shown that pour enzymes have the lowest stability and tissue preparations have the longest," notes the analyst. "While analyzing the lifetime of biosensors, three aspects of lifetime can be considered: the lifetime of the biosensor in use, the lifetime of the biosensor in storage, and the lifetime of the biological material stored separately." This being the case, researchers are striving to offer greater automation and convenience through noninvasive diagnostics. They are hoping to extend the longevity of the device by developing implantable yet completely automated and intelligent sensing platforms or sensors. The researchers' progress has attracted an increasing number of companies to this industry, yet the rate of growth is only moderate. This is mainly because being a standardized market, venture capitalists and acquiring companies have the freedom to wait and watch. This cautious approach has affected emerging companies significantly. Any small company with an innovative product, based on a robust technology, will have to be acquired or merge with a larger company to obtain return on investment and ease the commercialization process. This could prove daunting since bigger companies are facing a problem of plenty due to the presence of numerous similar products. The overlapping of technologies and products hinder each other’s potential market.
Once they figure out the companies that are profitable to acquire, large corporates will have to deal with the issue of rapid product obsolescence. This is because even though the rate of R&D is impressive in the biosensor industry, the products' market penetration is sluggish. Moreover, biosensor development – right from the R&D stage up to the production of the prototype product – is prohibitively expensive. "Commercialization of products would require companies to form strategic collaborations such as partnerships with original equipment manufacturers, licensing, and joint ventures," observes the analyst. "However, forming these associations is a time-consuming process and hence, even the newer technologies may seem obsolete to the end users." Researchers are hoping to overcome some of their challenges by developing products with greater unique selling propositions (USPs) by integrating wireless technology into the products as well as focusing on the creation of noninvasive monitoring systems and nanotechnology-based sensing devices.
Technologies
The following technologies are covered in this research:
- Blood analyte monitoring
- Disease detection
- Invasive biosensors
- Non-invasive biosensors
- Test kits
1. Executive Summary
Introduction
Emerging Biosensing Technologies and Their Applications
Key Technology Trends
Scope and Methodology
Scope of the Research Service
Research Methodology
2. Biosensors--An Overview
Technology Primer
Basic Description
Categories
Prelude
Performance
Emerging Diagnostic Biosensing System
3. Applications and Analysis
Technology Analysis
Technology Drivers and Restraints
Technology Challenges
Technology Segmentation and the Developer Focus
Competitive Environment for Medical Biosensing
Analyst Insights
Comments
Snapshot
4. Technical Developments
Developments by Companies
Noninvasive Glucose Monitoring--Portable Urine Glucose Meter
Voice-Based Blood Glucose Monitoring for Visually Impaired Diabetics
Intact Protein Microarrays
Real-Time PCR Assay for Respiratory Viruses
Low-Cost Portable Instrument for Testing Inhalable Drug Delivery Devices
DNA-Based Sensors for Detecting Volatile Compounds
TruArray for Rapid Diagnosis of Infectious Diseases
A High-Performance Low-Cost Analytical Device for Semen Analysis
Hologram-Based Sensors for Continuous Monitoring of Blood Glucose
An Innovative Sensor Technology for Quantification of Proteins
In Vivo Analysis of Blood Components
Electrochemical Sensors
Developments by Universities
Glucose Monitoring sans Pain and Blood
Electroanalysis Using Multiwalled Carbon Nanotube Nanoelectrode Arrays
5. Technology: AHP and Future
AHP
Definition of Criteria
AHP Process and Computation for Goal Node and Level 0 Criteria
AHP Process and Computation for Goal Node and Level 1 Criteria
Final Priorities and Analyst Insights
Future Forecast
Mechanistic Overview of Future Developments
Technology Road Map
6. Key Patents; Contacts
Key Patents
WIPO--Biosensor System Patents
WIPO--Allied Patents
Contacts
Database of Key Industry Participants
University Participants
7. Decision Support Database
Database Tables
Incidence of Diabetes by Region (2002—2012)
Percent Healthcare Expenditure in GDP by Region (2002--2012)
Government R & D Expenditure (Mn USD) in Biotechnology by Region (2002-2012)
Per Capita Healthcare Expenditure (USD) by Region (2001--2012)
Prevalence of Diabetes by Region (2002--2012
Total Healthcare Expenditure by Region (2002--2012)
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
